Mitobridge, Inc.

Name: Mitobridge, Inc.
Address: 1030 Massachusetts Ave, Cambridge, Massachusetts, United States, 02138-5302, Cambridge, 02138-5302
Telephone: '+1 617-401-9100

Cambridgebiotechnology

About

Mitobridge, Inc., now part of Astellas, is a biotechnology company focused on developing small molecule therapeutics that enhance mitochondrial functions. Founded in October 2013, the company aims to explore mitochondrial-targeted therapies linked to various diseases. Mitobridge's mission is to identify novel therapeutics that improve human health by targeting cellular pathways related to mitochondrial function. The company is engaged in the discovery and development of several key drug candidates, all currently in the preclinical phase. These include MA-0204 for muscular dystrophy, a STING inhibitor for autoimmune diseases, MK-0159 for myocardial reperfusion injury, and MiD49 for multiple mitochondrial dysfunction syndromes. Additionally, they are working on a patent for treating nervous system diseases. Mitobridge collaborates closely with Astellas Pharma and has partnerships with financial investors like MPM Capital and Longwood Fund.